

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.



China Health Group Limited
中國衛生集團有限公司

(Carrying on business in Hong Kong as CHG HS Limited)

(Incorporated in Bermuda with limited liability)

(Stock Code: 673)

**FURTHER DELAY IN DESPATCH OF CIRCULAR
IN RELATION TO**

- (I) SUBSCRIPTIONS OF NEW SHARES UNDER SPECIFIC MANDATE;**
- (II) PROPOSED RIGHTS ISSUE ON THE BASIS OF THREE (3) RIGHTS
SHARES FOR EVERY TEN (10) SHARES HELD ON THE RECORD DATE;**
- (III) CONNECTED TRANSACTION AND SPECIAL DEAL IN RELATION TO
THE UNDERWRITING AGREEMENT;**
- (IV) SPECIAL DEAL IN RELATION TO THE PLACING AGENT AGREEMENT;**
- AND**
- (V) APPLICATION FOR WHITEWASH WAIVER**

Financial Adviser to the Company



Independent Financial Adviser to the Company



Reference is made to (i) the announcement of China Health Group Limited (the “**Company**”) dated 22 May 2025 in relation to, among other things, the Proposal (the “**Capital Raising Announcement**”); and (ii) the announcement of the Company dated 12 June 2025 in relation to the delay in despatch of the circular (the “**Circular**”) in respect of the Proposal (collectively, the “**Announcements**”). Capitalised terms used herein shall have the same meanings as those defined in the Announcements unless the context otherwise requires.

As set out in the Announcements, the Circular containing, among others, (i) details of the Subscription Agreements, the Rights Issue, the Underwriting Agreement, the Placing Agent Agreement and the Whitewash Waiver; (ii) a letter of recommendation from the Independent Board Committee in respect of the Subscription Agreements, the Underwriting Agreement, the Placing Agent Agreement and the Whitewash Waiver; (iii) a letter of advice from the Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders in regards of the above; (iv) other information required under the Listing Rules and the Takeovers Code; and (v) a notice convening the SGM, was expected to be despatched to the Shareholders on or before 11 July 2025.

As additional time required to prepare and finalise certain information to be contained in the Circular including, among other things, certain financial information of the Group and the letter of advice from the Independent Financial Adviser, an application has been made to the Executive pursuant to Rule 8.2 of the Takeovers Code for its consent to extend the deadline for the despatch of the Circular to a date falling on or before 31 July 2025, and the Executive has indicated that it is minded to grant its consent for such extension.

The expected timetable for the Proposal as set out in the Capital Raising Announcement may be subject to change. Further announcement will be made by the Company as and when appropriate.

By order of the Board
China Health Group Limited
Chung Ho

Chief Executive Officer and Executive Director

Hong Kong, 11 July 2025

As of the date of this announcement, the Board comprises three executive Directors, namely, Mr. Zhang Fan (Chairman), Mr. Chung Ho and Mr. Xing Yong; two non-executive Directors, namely, Mr. Huang Lianhai and Mr. Wang Jingming; and four independent non-executive Directors, namely, Mr. Jiang Xuejun, Mr. Du Yanhua, Mr. Lai Liangquan and Ms. Yang Huimin.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.